RxDoctor Payments Data

Amy Hua

Neurology · Armonk, NYNPI 1467886630

Payments from drug & device makers

$2,193in general payments, 2019–2025

Across 108 payments — averaging $20.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • Medtronic$420
  • Biohaven Pharmaceutical Holding Company Ltd.$155
  • Genentech USA, Inc.$133
  • Biogen$125
  • Sanofi$125
  • plus $219 from 4 others

What the payments were for

  • Food & beverage$2,193100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,193 in reported general payments places this provider in the 55th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$167,901
Medicare patients
405
Services billed
4,257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate11$53,515
Nurtec OdtRimegepant Sulfate17$17,687
Duloxetine Hcl138$4,542
Gabapentin297$4,349
Azathioprine24$2,824
Memantine Hcl61$2,463
Pyridostigmine Bromide42$2,342
Carbidopa-LevodopaCarbidopa/Levodopa76$2,340
Pregabalin94$1,491
Primidone34$1,001
Quetiapine Fumarate62$993
Donepezil Hcl48$952
Baclofen30$849
Propranolol Hcl25$815
Carbidopa-Levodopa ErCarbidopa/Levodopa16$655

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$1,015$17,68717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,623 neurology providers in New York.

Other neurology in Armonk

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →